Assessment of adjuvant trastuzumab-associated cardiac toxicity in Korean patients with breast cancer: A single-center analysis

Chihwan Cha, Sung Gwe Ahn, Hak Min Lee, Hak Woo Lee, Seung Ah Lee, Jeong Joon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We performed this analysis to investigate the clinical presentation of trastuzumab-associated cardiac toxicity in Korean women. Method: 124 patients treated in a single institute from January 2006 to November 2011 with adjuvant trastuzumab therapy following primary surgery were identified from a database. We evaluated the cumulative incidence of cardiac toxicity, associated risk factors, and changes in cardiac function during trastuzumab treatment. Results: The median age of patients was 50 years (range 27-73). After 12 months of follow-up, the cumulative incidence of cardiac toxicity was 12.1% (grade I: 8.1%, grade II: 0.8%, grade III: 3.2%). In total, 4% of patients discontinued treatment due to cardiac dysfunction. The left ventricular ejection fraction (LVEF) recovered in all patients who discontinued or delayed treatment due to cardiac dysfunction following treatment discontinuation. The degree of the decrease in LVEF was large at 6 months after the initiation of treatment. A lower LVEF at baseline (<65%) was associated with cardiac toxicity. Conclusions: The low incidence of cardiac toxicity and the reversibility of cardiac dysfunction may validate the safety of trastuzumab treatment in Korean women with an acceptable baseline LVEF.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalOncology (Switzerland)
Volume85
Issue number4
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Breast Neoplasms
Stroke Volume
Therapeutics
Incidence
Trastuzumab
Cardiotoxicity
Databases
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cha, Chihwan ; Ahn, Sung Gwe ; Lee, Hak Min ; Lee, Hak Woo ; Lee, Seung Ah ; Joon, Jeong. / Assessment of adjuvant trastuzumab-associated cardiac toxicity in Korean patients with breast cancer : A single-center analysis. In: Oncology (Switzerland). 2013 ; Vol. 85, No. 4. pp. 228-234.
@article{80b786f0558d44a29efeec04133e8dbf,
title = "Assessment of adjuvant trastuzumab-associated cardiac toxicity in Korean patients with breast cancer: A single-center analysis",
abstract = "Background: We performed this analysis to investigate the clinical presentation of trastuzumab-associated cardiac toxicity in Korean women. Method: 124 patients treated in a single institute from January 2006 to November 2011 with adjuvant trastuzumab therapy following primary surgery were identified from a database. We evaluated the cumulative incidence of cardiac toxicity, associated risk factors, and changes in cardiac function during trastuzumab treatment. Results: The median age of patients was 50 years (range 27-73). After 12 months of follow-up, the cumulative incidence of cardiac toxicity was 12.1{\%} (grade I: 8.1{\%}, grade II: 0.8{\%}, grade III: 3.2{\%}). In total, 4{\%} of patients discontinued treatment due to cardiac dysfunction. The left ventricular ejection fraction (LVEF) recovered in all patients who discontinued or delayed treatment due to cardiac dysfunction following treatment discontinuation. The degree of the decrease in LVEF was large at 6 months after the initiation of treatment. A lower LVEF at baseline (<65{\%}) was associated with cardiac toxicity. Conclusions: The low incidence of cardiac toxicity and the reversibility of cardiac dysfunction may validate the safety of trastuzumab treatment in Korean women with an acceptable baseline LVEF.",
author = "Chihwan Cha and Ahn, {Sung Gwe} and Lee, {Hak Min} and Lee, {Hak Woo} and Lee, {Seung Ah} and Jeong Joon",
year = "2013",
month = "11",
day = "1",
doi = "10.1159/000354836",
language = "English",
volume = "85",
pages = "228--234",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "4",

}

Assessment of adjuvant trastuzumab-associated cardiac toxicity in Korean patients with breast cancer : A single-center analysis. / Cha, Chihwan; Ahn, Sung Gwe; Lee, Hak Min; Lee, Hak Woo; Lee, Seung Ah; Joon, Jeong.

In: Oncology (Switzerland), Vol. 85, No. 4, 01.11.2013, p. 228-234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of adjuvant trastuzumab-associated cardiac toxicity in Korean patients with breast cancer

T2 - A single-center analysis

AU - Cha, Chihwan

AU - Ahn, Sung Gwe

AU - Lee, Hak Min

AU - Lee, Hak Woo

AU - Lee, Seung Ah

AU - Joon, Jeong

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background: We performed this analysis to investigate the clinical presentation of trastuzumab-associated cardiac toxicity in Korean women. Method: 124 patients treated in a single institute from January 2006 to November 2011 with adjuvant trastuzumab therapy following primary surgery were identified from a database. We evaluated the cumulative incidence of cardiac toxicity, associated risk factors, and changes in cardiac function during trastuzumab treatment. Results: The median age of patients was 50 years (range 27-73). After 12 months of follow-up, the cumulative incidence of cardiac toxicity was 12.1% (grade I: 8.1%, grade II: 0.8%, grade III: 3.2%). In total, 4% of patients discontinued treatment due to cardiac dysfunction. The left ventricular ejection fraction (LVEF) recovered in all patients who discontinued or delayed treatment due to cardiac dysfunction following treatment discontinuation. The degree of the decrease in LVEF was large at 6 months after the initiation of treatment. A lower LVEF at baseline (<65%) was associated with cardiac toxicity. Conclusions: The low incidence of cardiac toxicity and the reversibility of cardiac dysfunction may validate the safety of trastuzumab treatment in Korean women with an acceptable baseline LVEF.

AB - Background: We performed this analysis to investigate the clinical presentation of trastuzumab-associated cardiac toxicity in Korean women. Method: 124 patients treated in a single institute from January 2006 to November 2011 with adjuvant trastuzumab therapy following primary surgery were identified from a database. We evaluated the cumulative incidence of cardiac toxicity, associated risk factors, and changes in cardiac function during trastuzumab treatment. Results: The median age of patients was 50 years (range 27-73). After 12 months of follow-up, the cumulative incidence of cardiac toxicity was 12.1% (grade I: 8.1%, grade II: 0.8%, grade III: 3.2%). In total, 4% of patients discontinued treatment due to cardiac dysfunction. The left ventricular ejection fraction (LVEF) recovered in all patients who discontinued or delayed treatment due to cardiac dysfunction following treatment discontinuation. The degree of the decrease in LVEF was large at 6 months after the initiation of treatment. A lower LVEF at baseline (<65%) was associated with cardiac toxicity. Conclusions: The low incidence of cardiac toxicity and the reversibility of cardiac dysfunction may validate the safety of trastuzumab treatment in Korean women with an acceptable baseline LVEF.

UR - http://www.scopus.com/inward/record.url?scp=84888220825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888220825&partnerID=8YFLogxK

U2 - 10.1159/000354836

DO - 10.1159/000354836

M3 - Article

C2 - 24081024

AN - SCOPUS:84888220825

VL - 85

SP - 228

EP - 234

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -